

£ 78.00
Rejuran i Polynucleotides Eye Area 1x1ml is a specialised polynucleotide injectable for the periocular region, forming part of the established Rejuran range manufactured by PharmaResearch Co., Ltd., South Korea. It is designed for professional aesthetic practitioners who are looking to address visible signs of ageing and deterioration in skin quality around the eyes.
The eye area presents particular challenges in aesthetic medicine. Periocular skin is significantly thinner and more delicate than many other facial areas, and patients frequently present with fine lines, dehydration, reduced elasticity, crepey texture and early photoageing. Conventional volumising dermal fillers are not always the preferred approach when the primary concern is skin quality rather than loss of structural volume. This is where a dedicated PN eye skin booster such as Rejuran i can have a role within a practitioner-led rejuvenation programme.
Polynucleotides for Skin Rejuvenation
The principal technology behind Rejuran is polynucleotides (PN). Polynucleotides are purified DNA-derived molecules that have become increasingly established within the medical aesthetics sector as injectable skin-quality treatments.
Rather than functioning primarily as a conventional volumising filler, PN treatments are intended to support the biological environment of the skin and promote a healthier-looking tissue structure. This makes Rejuran i particularly relevant for practitioners whose treatment objectives centre on skin regeneration, hydration, elasticity and texture improvement.
The Rejuran range is associated with the use of highly purified polynucleotides derived from salmon DNA. The manufacturer has developed different Rejuran formulations for different anatomical and aesthetic requirements, with Rejuran i specifically designed for treatment around the eyes.
Designed for the Periocular Area
The periocular region requires careful product selection because of its delicate anatomy. Rejuran i is formulated specifically for the eye contour, making it distinct from the standard Rejuran formulations used for broader facial treatment.
The treatment may be incorporated into protocols for patients presenting with periocular fine lines, dry-looking skin, reduced elasticity and crepey texture. The objective is to improve overall skin quality rather than create a conventional filling or contouring effect.
For aesthetic clinics, this makes Rejuran i particularly relevant to patients who want a subtle improvement in the appearance of the eye area without significantly altering facial volume or proportions.
Skin Quality Rather Than Traditional Volumisation
One of the important distinctions practitioners should communicate when discussing Rejuran i is that it is not primarily a conventional dermal filler.
Cross-linked HA fillers are commonly selected when the treatment objective involves replacing lost volume, enhancing projection or modifying facial contours. Rejuran i, by comparison, is positioned as a polynucleotide skin booster / biostimulatory injectable, where the treatment objective is focused more on the quality and appearance of the skin.
This distinction is useful when developing patient-specific treatment plans. A patient presenting with hollowing caused by significant structural volume loss may require a different approach from a patient whose primary concern is fine periocular lines and poor skin quality.
Fine Lines and Periocular Ageing
The eye area is one of the first regions where patients may notice visible signs of ageing. Repeated facial movement, environmental exposure, reduced skin elasticity and natural ageing can contribute to crow's feet, fine lines and crepey skin.
Rejuran i can be incorporated into professional treatment protocols designed to improve the appearance of these concerns. The PN-based treatment approach is intended to support progressive skin-quality improvement rather than produce a dramatic immediate transformation.
This makes it suitable for practitioners who favour natural-looking, progressive aesthetic outcomes.
Treatment Planning
Rejuran i treatment should form part of an individualised clinical assessment. Practitioners should consider the patient's age, skin condition, degree of photoageing, elasticity, previous aesthetic treatments and expectations.
The periocular region contains important anatomical structures, including the superficial vascular network and orbital structures. Consequently, treatment should only be performed by appropriately trained practitioners with a thorough understanding of periocular anatomy and injectable treatment techniques.
The manufacturer's current Instructions for Use (IFU) should be followed for product preparation, injection technique, treatment depth, dosage and treatment intervals.
Professional Aesthetic Applications
Rejuran i can be considered as part of a broader non-surgical facial rejuvenation protocol. Depending on patient presentation, practitioners may combine different treatment modalities to address multiple aspects of facial ageing.
For example, where a patient presents with significant volume loss, an appropriate dermal filler may address structural deficiency, while a PN skin booster can be considered for skin quality. These products have different mechanisms and should not be considered interchangeable.
Rejuran i therefore occupies a specific position within the aesthetic medicine market as a periocular polynucleotide treatment.
Gradual Skin Improvement
Patients seeking injectable skin rejuvenation are increasingly interested in treatments that produce subtle and progressive improvements. Polynucleotide treatments are often selected within this context because the clinical objective is to improve the appearance and quality of the skin over time rather than produce an immediate volumising change.
For clinics, this provides an opportunity to incorporate Rejuran i into structured skin rejuvenation programmes, particularly for patients concerned about the early signs of periocular ageing.
Practitioners should ensure that patient expectations remain realistic. Individual outcomes can vary according to skin condition, age, lifestyle, degree of photoageing and biological response.
Product Selection Within the Rejuran Range
Rejuran is available in different formulations designed for different treatment objectives and anatomical areas. Rejuran i should be distinguished from formulations intended for broader facial treatment.
The i formulation is specifically associated with the delicate eye area, making it the appropriate Rejuran formulation to consider when the treatment objective is periocular skin rejuvenation.
Correct product selection is important because different formulations can have different characteristics and intended applications. Practitioners should always verify the current manufacturer documentation before treatment.
Why Rejuran i Can Be Valuable for Clinics
For aesthetic clinics, Rejuran i offers a treatment option within the growing polynucleotide skin booster category. It can complement established procedures such as injectable skin boosters, chemical peels, microneedling and other non-surgical rejuvenation treatments where clinically appropriate.
Its main appeal is the focus on skin quality rather than facial augmentation. This can be particularly valuable for patients who want their eye area to look healthier, smoother and more youthful without appearing noticeably "filled".
Overall, Rejuran i Polynucleotides Eye Area 1x1ml provides aesthetic practitioners with a specialised PN injectable designed for the delicate periocular region. Its focus on skin rejuvenation, fine lines, elasticity and overall skin quality makes it a useful addition to professional eye-area rejuvenation protocols.
Treatment Areas
Rejuran i is specifically associated with the periocular / eye area, including:
Treatment should be performed according to the manufacturer's current IFU and by a suitably trained practitioner with appropriate knowledge of periocular anatomy.
Usage
Rejuran i 1x1ml is supplied as an injectable preparation intended for professional clinical use.
The product should be administered only by appropriately qualified healthcare professionals experienced in injectable aesthetic procedures.
The appropriate injection technique, depth, dosage, treatment intervals and preparation requirements should be determined according to the current manufacturer IFU and local regulatory requirements.
Because the eye area is anatomically complex and highly vascularised, practitioners should use appropriate clinical assessment and aseptic technique and should be familiar with the management of complications associated with periocular injectable procedures.
Ingredient ListPolynucleotides (PN)
The principal active component of Rejuran i is purified polynucleotide (PN) derived from salmon DNA. Polynucleotides are used in aesthetic medicine as a skin-quality and biostimulatory treatment component.
PN-based treatments are intended to support the skin's regenerative environment and contribute to improvements in skin texture, elasticity and overall skin quality.
Product Volume
1 × 1ml syringe
The precise concentration and composition should be verified against the current manufacturer packaging and IFU supplied with the product.
Product Dimensions / Size
1 × 1ml
Product Duration
The duration of results varies between patients and depends on factors including age, skin condition, lifestyle, degree of photoageing, treatment protocol and individual biological response.
Rejuran treatments are generally positioned as part of a course-based skin rejuvenation programme, with maintenance treatments potentially required to sustain results. Practitioners should follow the manufacturer's current treatment recommendations rather than guaranteeing a fixed duration.
Manufactured By
PharmaResearch Co., Ltd. — South Korea
PharmaResearch is the South Korean pharmaceutical and biotechnology company behind the Rejuran product range.
Compare insurance quotes from trusted partners.
255 products
6,168 sold